Currently, RDIF has experience in the successful joint implementation of more than 80 projects with foreign partners, totaling more than RUB 1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries and total more than $40 bn.
Since the start of the COVID-19 pandemic RDIF has played a key role in fighting the virus in Russia. Working jointly with some of the world’s top institutional investors, we have selected and funded what we believe are the most promising COVID-19 testing systems, drugs and vaccines. RDIF supports the development of Russia’s COVID-19 vaccine by the Gamaleya Center and is investing in mass production of the vaccine by RDIF portfolio companies.